Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Asthma and Allergy"
DOI: 10.2147/jaa.s189676
Abstract: Purpose Patients with severe asthma are eligible for asthma-specific biologics as add-on therapies, such as mepolizumab and omalizumab, when optimized controller therapies are unable to control their symptoms. However, few real-world data are available to… read more here.
Keywords: patients prescribed; asthma; prescribed mepolizumab; mepolizumab omalizumab ... See more keywords